ALK.CAR-T

News alerts, weekly reports and conference planners

Company:

Celldex

Drug class:

ALK-targeted CAR-T immunotherapy

‹

›

2years

ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. (PubMed, Cancer Cell)

Mechanistically, ALK inhibitors impair tumor growth and upregulate the expression of ALK, thereby facilitating the activity of ALK.CAR-T cells against neuroblastoma. Thus, while neither ALK inhibitors nor ALK.CAR-T cells will likely be sufficient as monotherapy in neuroblastoma with low ALK density, their combination specifically enhances therapeutic efficacy.

2 years ago

Journal • CAR T-Cell Therapy • IO biomarker

ALK (Anaplastic lymphoma kinase)

Lorbrena (lorlatinib) • ALK.CAR-T

over2years

ALK chimeric antigen receptor T cells cooperate with ALK inhibitors to target neuroblastoma cells with low target density (EACR 2023)

These findings provide insights into the potential of ALK.CAR-T cells as a novel therapeutic strategy for neuroblastoma. A Phase I clinical trial to test ALK.CAR-T cells in combination with ALK TKIs in children with refractory/relapsed neuroblastoma is being implemented based on these results.

over 2 years ago

CAR T-Cell Therapy • IO biomarker

ALK (Anaplastic lymphoma kinase)

ALK.CAR-T